journal article·2021-08-11

Smart Design of a pH-Responsive System Based on pHLIP-Modified Magnetite Nanoparticles for Tumor MRI

Alexander M. Demin, Alexandra G. Pershina, Artem S. Minin, Olga Ya. Brikunova, Aidar M. Murzakaev, Natalya A. Perekucha, Alexander V. Romashchenko, Oleg B. Shevelev, Mikhail A. Uimin, Iliya V. Byzov, Dina Malkeyeva, Elena Kiseleva, Lina V. Efimova, Sergey V. Vtorushin, Ludmila M. Ogorodova, Victor P. Krasnov

ACS Applied Materials & Interfaces· Volume 13· Issue 31
Publisher page

Abstract

Magnetic Fe3O4 nanoparticles (MNPs) are often used to design agents enhancing contrast in magnetic resonance imaging (MRI) that can be considered as one of the efficient methods for cancer diagnostics. At present, increasing the specificity of the MRI contrast agent accumulation in tumor tissues remains an open question and attracts the attention of a wide range of researchers. One of the modern methods for enhancing the efficiency of contrast agents is the use of molecules for tumor acidic microenvironment targeting, for example, pH-low insertion peptide (pHLIP). We designed novel organosilicon MNPs covered with poly(ethylene glycol) (PEG) and covalently modified by pHLIP. To study the specific features of the binding of pHLIP-modified MNPs to cells, we also obtained nanoconjugates with Cy5 fluorescent dye embedded in the SiO2 shell. The nanoconjugates obtained were characterized by transmission electron microscopy (TEM), attenuated total reflection (ATR), diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), dynamic light scattering (DLS), UV and fluorescence spectrometry, thermogravimetric analysis (TGA), CHN elemental analyses, and vibrating sample magnetometry. Low cytotoxicity and high specificity of cellular uptake of pHLIP-modified MNPs at pH 6.4 versus 7.4 (up to 23-fold) were demonstrated in vitro. The dynamics of the nanoconjugate accumulation in the 4T1 breast cancer orthotopically grown in BALB/c mice and MDA-MB231 xenografts was evaluated in MRI experiments. Biodistribution and biocompatibility studies of the obtained nanoconjugate showed no pathological change in organs and in the blood biochemical parameters of mice after MNP administration. A high accumulation rate of pHLIP-modified MNPs in tumor compared with PEGylated MNPs after their intravenous administration was demonstrated. Thus, we propose a promising approach to design an MRI agent with the tumor acidic microenvironment targeting ability.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Yekaterinburg, Russia

Siberian State Medical University, 634050 Tomsk, Russia

Research School of Chemical and Biomedical Engineering, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia

Mikheev Institute of Metal Physics, Russian Academy of Sciences (Ural Branch), 620990 Yekaterinburg, Russia

Institute of Electrophysics, Russian Academy of Sciences (Ural Branch), 620016 Yekaterinburg, Russia

Institute of Natural Sciences and Mathematics, Ural Federal University, 620000 Yekaterinburg, Russia

Institute of Cytology and Genetics, Russian Academy of Sciences (Siberian Branch), 630090 Novosibirsk, Russia

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia

Funding

Ministry of Health of the Russian Federation · TPU development program

References (61)

Show source-provided references
1. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
2. 10.1039/C7CS00657H10.1039/C7CS00657H ↗
3. 10.1016/j.drudis.2020.04.01810.1016/j.drudis.2020.04.018 ↗
4. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
5. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
6. 10.1016/j.msec.2019.01.06610.1016/j.msec.2019.01.066 ↗
7. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
8. 10.1016/j.actbio.2019.11.02710.1016/j.actbio.2019.11.027 ↗
9. 10.1021/acs.jmedchem.9b0051110.1021/acs.jmedchem.9b00511 ↗
10. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
11. 10.1038/nature1262510.1038/nature12625 ↗
12. 10.1073/pnas.92.19.899910.1073/pnas.92.19.8999 ↗
13. 10.1021/acsnano.6b0087010.1021/acsnano.6b00870 ↗
14. 10.1073/pnas.091433010710.1073/pnas.0914330107 ↗
15. 10.3109/09687688.2010.50928510.3109/09687688.2010.509285 ↗
16. Tannock I. F. · Cancer Res. · 1989 · 49 · 4373
17. 10.1007/s10334-005-0013-z10.1007/s10334-005-0013-z ↗
18. 10.1016/j.abb.2014.11.00210.1016/j.abb.2014.11.002 ↗
19. 10.1073/pnas.101440310710.1073/pnas.1014403107 ↗
20. 10.1021/bi301647y10.1021/bi301647y ↗
21. 10.1039/C6RA13178F10.1039/C6RA13178F ↗
22. 10.1016/j.nano.2019.10208610.1016/j.nano.2019.102086 ↗
23. 10.1021/jacs.0c0065010.1021/jacs.0c00650 ↗
24. 10.1016/j.actbio.2017.03.04610.1016/j.actbio.2017.03.046 ↗
25. 10.1021/acssensors.6b0039610.1021/acssensors.6b00396 ↗
26. 10.1021/acsami.6b1323710.1021/acsami.6b13237 ↗
27. 10.1021/acsami.7b1084010.1021/acsami.7b10840 ↗
28. 10.1186/s12967-017-1156-110.1186/s12967-017-1156-1 ↗
29. 10.1016/j.dib.2019.10506210.1016/j.dib.2019.105062 ↗
30. 10.1109/TMAG.1981.106118810.1109/TMAG.1981.1061188 ↗
31. 10.1016/j.colsurfb.2020.11087910.1016/j.colsurfb.2020.110879 ↗
32. 10.1021/mp800049w10.1021/mp800049w ↗
33. 10.1016/j.jddst.2020.10231610.1016/j.jddst.2020.102316 ↗
34. 10.1021/acsnano.6b0287610.1021/acsnano.6b02876 ↗
35. 10.1021/acs.chemrestox.6b0029810.1021/acs.chemrestox.6b00298 ↗
36. 10.1002/adma.20120529210.1002/adma.201205292 ↗
37. 10.1016/j.apsusc.2019.14456510.1016/j.apsusc.2019.144565 ↗
38. 10.1016/j.mseb.2020.11483510.1016/j.mseb.2020.114835 ↗
39. 10.1016/j.ceramint.2017.10.18410.1016/j.ceramint.2017.10.184 ↗
40. 10.1016/j.colsurfb.2020.11127410.1016/j.colsurfb.2020.111274 ↗
41. 10.1021/jp900868d10.1021/jp900868d ↗
42. 10.1021/cm302828d10.1021/cm302828d ↗
43. 10.1002/anie.20080246910.1002/anie.200802469 ↗
44. 10.1021/cm400711h10.1021/cm400711h ↗
45. 10.1016/j.apsusc.2016.07.06110.1016/j.apsusc.2016.07.061 ↗
46. 10.1021/acs.langmuir.7b0402310.1021/acs.langmuir.7b04023 ↗
47. 10.1016/j.apsusc.2018.01.14710.1016/j.apsusc.2018.01.147 ↗
48. 10.1039/C5CS00541H10.1039/C5CS00541H ↗
49. 10.1016/0021-9797(68)90272-510.1016/0021-9797(68)90272-5 ↗
50. 10.2147/IJN.S11188010.2147/IJN.S111880 ↗
51. 10.1016/j.trac.2016.01.01210.1016/j.trac.2016.01.012 ↗
52. 10.1039/C3AN01684F10.1039/C3AN01684F ↗
53. 10.1016/j.apsusc.2010.10.08110.1016/j.apsusc.2010.10.081 ↗
54. 10.1021/acsomega.9b0024510.1021/acsomega.9b00245 ↗
55. 10.1016/j.mencom.2019.11.00810.1016/j.mencom.2019.11.008 ↗
56. 10.1016/j.mencom.2013.12.00610.1016/j.mencom.2013.12.006 ↗
57. 10.1039/C4CS00487F10.1039/C4CS00487F ↗
58. 10.2147/IJN.S6853910.2147/IJN.S68539 ↗
59. 10.1021/nn204591r10.1021/nn204591r ↗
60. 10.1021/acs.chemmater.5b0094410.1021/acs.chemmater.5b00944 ↗
61. 10.3978/j.issn.2223-4292.2011.08.0310.3978/j.issn.2223-4292.2011.08.03 ↗